LENVATOL 4 Mg (LENVATINIB 4 MG)
| Active Ingredient | Lenvatinib |
|---|---|
| Manufacturers | Cipla Limited |
| Indications | Thyroid cancer |
| Strength | 4mg |
| Packaging | 10 Tablets in 1 Strip |
| Delivery Time | 6 To 15 days |
LENVATOL 4 mg contains Lenvatinib, a targeted cancer treatment used for patients with advanced or metastatic thyroid cancer, renal cell carcinoma (kidney cancer), and hepatocellular carcinoma (liver cancer). As a tyrosine kinase inhibitor (TKI), Lenvatinib blocks the growth signals cancer cells need to multiply, helping to shrink tumors and slow disease progression.
LENVATOL 4 mg is often prescribed either alone or in combination with other therapies, depending on the type and stage of cancer. Taken orally once daily, it should always be used under strict oncologist supervision, as dosage and duration vary per individual.
Important: Close monitoring of liver function, blood pressure, and side effects is necessary during treatment.








There are no reviews yet.